(ZTS) Zoetis - Ratings and Ratios

Zoetis Inc. (NYSE:ZTS) is a global leader in animal health, specializing in the discovery, development, and commercialization of a diverse portfolio of products and services for livestock and companion animals. The companys offerings include pharmaceuticals such as parasiticides, vaccines, dermatology treatments, anti-infectives, and pain management solutions, as well as diagnostics, biodevices, genetic tests, and precision animal health products. Zoetis serves veterinarians, livestock producers, and pet owners worldwide, providing solutions for species ranging from cattle, swine, and poultry to dogs, cats, and horses. Its diagnostics portfolio includes point-of-care testing, rapid immunoassay tests, and reference laboratory services. The company also offers non-pharmaceutical products like nutritionals and precision health solutions. Zoetis collaborates with Blacksmith Medicines, Inc. to develop novel antibiotics for animal health, underscoring its commitment to innovation. Founded in 1950 and headquartered in Parsippany, New Jersey, Zoetis has established itself as a key player in advancing animal health globally.

Zoetis Inc. operates with a strong focus on research and development, ensuring a steady pipeline of innovative products. Its market leadership is supported by a robust distribution network and strategic partnerships. The companys financial health is reflected in its market capitalization of over $71 billion, with a trailing P/E ratio of 29.13 and a forward P/E of 27.17, indicating investor confidence in its growth prospects. Zoetiss return on equity (RoE) of 52.12% highlights its operational efficiency and profitability. The stock currently trades at $148.67, with a 20-day average volume of 2,868,700 shares. Technical indicators such as SMA 20, SMA 50, and SMA 200 suggest the stock is currently in a downtrend, while the ATR of 5.03 reflects moderate volatility.